Dengue NS1 & Typhoid IgG/IgM Combo Rapid Test Kits: Sourcing Strategy for Tropical Medicine Importers

TL;DR Summary

• Best dual-pathogen panel for government tenders: Dengue NS1+IgG/IgM + Typhoid IgG/IgM (same sample, same storage, one supplier)
• Combined per-patient cost: Under $1.00 FOB at procurement volumes (Dengue Combo $0.34-0.80 + Typhoid ~$0.10)
• Critical warning: Malaria cannot be added to this panel — it requires erythrocyte lysis with incompatible buffer chemistry
• Storage: Both tests stable at 4-30°C for 24 months; verify real-time stability data before committing to any OEM contract
• Certification must-haves for tender qualification: ISO 13485 + MDSAP (covers FDA/Health Canada/TGA/ANVISA/PMDA) + CE IVDR technical file

1. The Tropical Fever Diagnostic Gap: Why Combo Testing Matters Right Now

Dengue and typhoid fever are syndromically indistinguishable during the first 72 hours of illness. Both present with high fever, severe headache, myalgia, and gastrointestinal symptoms — and in tropical medicine settings where PCR and blood culture are not routinely available, clinicians must treat empirically. That means antibiotics for suspected typhoid plus supportive care for suspected dengue, often simultaneously, until lab results arrive days later.

The scale of the problem is staggering. According to the World Health Organization, the Region of the Americas alone reported over 7 million dengue cases by the end of April 2024, exceeding the previous annual high of 4.6 million set in 2023. By July 2025, WHO had recorded over 4 million cases and 3,000+ deaths across 97 countries globally (WHO Dengue Fact Sheet). Meanwhile, typhoid fever continues to cause an estimated 7.1 million new cases and 93,000 deaths annually worldwide (GBD 2021 Typhoid Study).

For importers and procurement agencies serving endemic countries, this dual burden creates both a clinical imperative and a commercial opportunity. Hospitals and clinics need rapid, simultaneous differential diagnosis for febrile patients — and they need it at a price point that public health budgets can sustain. The Dengue NS1 + Typhoid IgG/IgM combination, sourced as separate cassette tests from a single manufacturer, addresses this need with technical coherence that a Dengue + Malaria panel simply cannot match.

2. Dengue NS1 + Typhoid IgG/IgM: The Technically Viable Combination (and What Won’t Work)

This dual-pathogen panel works because both tests operate on the same lateral flow chromatographic immunoassay platform with identical sample matrices. Both Dengue NS1 antigen detection and Typhoid IgG/IgM serology accept whole blood, serum, or plasma — meaning a single venipuncture yields enough sample for both cassettes. The buffer systems are compatible, the incubation time is comparable (15-20 minutes for both), and the storage requirements are identical at 4-30°C.

I want to address a misconception I have seen in procurement specifications across Southeast Asia and West Africa. Some tender documents request a single-cassette Dengue + Malaria + Typhoid triple test. This does not exist as a technically viable product, and any manufacturer claiming otherwise is either misrepresenting their product or selling a panel of separate cassettes under one SKU.

The reason is biochemical, not commercial. Malaria rapid diagnostic tests — whether detecting PfHRP2, pLDH, or aldolase — require erythrocyte lysis to release intraerythrocytic parasite antigens. This means the blood sample must be treated with a lysis buffer that ruptures red blood cell membranes. Dengue NS1 is a soluble viral protein circulating in plasma, and Typhoid IgG/IgM antibodies are serum proteins. They do not require — and in fact are degraded by — the lysis conditions necessary for malaria antigen release.

Anyone who has worked on the bench knows: when you lyse erythrocytes, you introduce hemoglobin, cellular debris, and buffer constituents that interfere with the capillary flow and antigen-antibody binding kinetics of a standard lateral flow strip. The result is either a high background invalidating the test or, worse, a false-negative NS1 reading in a patient with active dengue viremia.

The correct sourcing strategy is therefore: source Dengue NS1+IgG/IgM and Typhoid IgG/IgM as two separate cassette tests from the same OEM manufacturer, and source malaria rapid tests from the same supplier as a separate line item with its own lysis buffer protocol. This gives you logistical consolidation without compromising diagnostic accuracy.

3. Technical Specifications: What Importers Should Verify Before Ordering

Not all lateral flow rapid tests are built to the same standard — and in the IVD industry, the difference between a product that clears customs and one that fails a tender inspection often comes down to three technical parameters.

3.1 Sensitivity and Specificity Benchmarks

For Dengue NS1 detection via lateral flow immunoassay, published clinical studies show NS1 rapid test sensitivity in the range of 60-85% depending on serotype and day of fever, with specificity routinely exceeding 90% (Pokhrel et al., 2024). However, these figures vary dramatically by manufacturer. When evaluating an OEM supplier, insist on seeing the full clinical evaluation report — not just the summary table — and verify the following:

• NS1 sensitivity stratified by dengue serotype (DENV-1 through DENV-4). A manufacturer who only tested against DENV-2 has not demonstrated pan-serotype performance.
• IgM/IgG sensitivity stratified by primary vs. secondary infection. Secondary dengue shows different antibody kinetics — a test validated only on primary-infection samples may miss IgG-dominant secondary cases.
• Typhoid IgG/IgM specificity against non-typhoidal Salmonella and other Enterobacteriaceae. Cross-reactivity with S. Paratyphi A/B is common and must be documented.

3.2 Storage and Stability: The 4-30°C Requirement

Storage conditions must be 4-30°C, not 2-30°C. This is not a minor distinction. At 2°C, some buffer formulations begin to precipitate, and repeated freeze-thaw cycling — which occurs when shipments move through unheated cargo holds in temperate-climate transit hubs — can denature the conjugated antibodies on the test strip. A manufacturer who lists 2-30°C on their IFU (Instructions for Use) may be using a buffer that has not been validated for precipitation resistance at the lower end.

Verify that the manufacturer has completed real-time stability studies demonstrating 24-month shelf life at 4-30°C storage. Accelerated stability data (e.g., 37°C for 14 days) is useful for screening but is not a substitute for real-time data. Testsea, for example, maintains 24-30 month real-time stability data as part of its CE IVDR technical file documentation — a detail that matters when a regulatory authority audits your import dossier.

3.3 Sample Volume and Workflow Compatibility

Dengue NS1 detection typically requires 50-75 μL of serum or plasma for the antigen well, while the antibody (IgG/IgM) portion requires 5-10 μL. Typhoid IgG/IgM testing typically uses 5 μL. A well-designed OEM product will have these volumes clearly marked on the cassette and in the IFU — and a well-prepared importer will verify that the buffer bottle dropper delivers a consistent drop volume (±5% tolerance) across all production lots.

4. Regulatory Essentials: Certifications That Actually Matter in Tender Bids

I have reviewed hundreds of tropical medicine procurement tenders, and the minimum certification bar has risen sharply since 2023. Five years ago, CE marking alone was sufficient for most markets. Today, government tender documents from Indonesia to Nigeria routinely require ISO 13485 plus at least one additional GMP recognition mechanism.

The gold standard for multi-market access is MDSAP (Medical Device Single Audit Program). A single MDSAP audit satisfies the quality management system requirements of five regulatory authorities simultaneously: the U.S. FDA, Health Canada, Australia’s TGA, Brazil’s ANVISA, and Japan’s PMDA (FDA MDSAP Program). For an importer, this means one factory audit covers regulatory filings in multiple destination markets — a non-trivial reduction in compliance overhead.

Beyond MDSAP, verify that the manufacturer holds CE certification under the IVDR (In Vitro Diagnostic Regulation), not the legacy IVDD. The transition deadline has passed, and products still certified under IVDD will face increasing customs scrutiny in EU and EU-aligned markets. A manufacturer with a complete IVDR technical file — including clinical performance evaluation, post-market surveillance plan, and real-time stability data — is positioned to maintain uninterrupted market access through regulatory transitions.

For tender submissions, the importer should also confirm that the manufacturer can provide:

• Certificate of Free Sale (CFS) issued by the Chinese competent authority (NMPA)
• Certificate of Analysis (CoA) per production batch, with QC release specifications
• Device Master Record (DMR) summary demonstrating design control traceability
• ISO 14971 risk management file covering all identified hazards for the intended use population

5. Pricing Intelligence: What China-Made Combo Tests Actually Cost in 2026

Based on publicly available China export pricing data, here is the current FOB price landscape for lateral flow rapid tests in the tropical disease category:

• Dengue Combo (NS1 + IgG/IgM) cassette: $0.34 – $0.80 per test, FOB China (MOQ 1,000-5,000 units)
• Typhoid IgG/IgM cassette: approximately $0.10 per test, FOB China
• Malaria Pf/Pv or Pf/Pan cassette: $0.15 – $0.35 per test, FOB China (separate line item with lysis buffer)

These prices represent the wholesale FOB range from verified Chinese IVD manufacturers with legitimate ISO 13485 certification. Prices below $0.30 for a Dengue NS1 combo cassette should trigger due diligence — at that price point, the manufacturer is either cutting costs on monoclonal antibody quality (which directly impacts sensitivity) or operating without full regulatory compliance overhead.

The combined per-patient cost for Dengue + Typhoid dual screening at procurement volumes is approximately $0.44-0.90 — well under the $1.00 threshold that many national procurement agencies use as a benchmark for cost-effective rapid screening. At 50,000-unit order volume, the per-unit price typically approaches the lower end of the range due to production batch optimization at the factory level.

When comparing quotes, factor in the following cost differentiators that are often buried in the fine print:

• Buffer inclusion: Some manufacturers price buffer bottles separately ($0.02-0.05 per bottle)
• Packaging format: Individual pouch vs. bulk packaging affects landed cost through volumetric weight differences
• IFU language localization: English/Portuguese/French/Arabic IFU printing typically adds $0.01-0.03 per unit
• Shelf-life at delivery: Insist on minimum 18 months remaining at port of entry — a 24-month product shipped with 6 months remaining is effectively a clearance risk

6. OEM Supply Chain Strategy: Building a Reliable Tropical Panel Portfolio

The most cost-efficient procurement model for tropical disease rapid tests is not buying individual SKUs from multiple suppliers — it is building a consolidated OEM partnership with a single ISO 13485-certified manufacturer that can deliver the entire febrile disease panel from one factory.

Here is what a well-structured tropical medicine rapid test portfolio looks like when sourced through a single OEM partner:

• Core panel (single-sample compatible, 4-30°C storage): Dengue NS1+IgG/IgM Combo + Typhoid IgG/IgM
• Extension panel (separate buffer, 4-30°C storage): Malaria Pf/Pv or Pf/Pan (with dedicated lysis buffer)
• Optional additions (same platform, 4-30°C storage): Chikungunya IgM/IgG, Zika IgM/IgG, Leptospira IgM/IgG, HBsAg, HCV, HIV 1/2

When evaluating an OEM manufacturer for this portfolio, I recommend the following due diligence sequence:

1. Verify production scale. A facility producing under 100 million tests per year will struggle with lot-to-lot consistency at the sensitivity margins required for NS1 detection. Testsea operates from a 56,000 m² IVD production base with over 500 employees and annual capacity exceeding 3 billion diagnostic kits.
2. Request retained sample retesting data. ISO 13485 requires manufacturers to retain samples from each production lot and retest them at defined intervals. Ask for the last 12 months of retained sample data for the Dengue NS1 product line — this is your best indicator of real-world lot consistency.
3. Evaluate regulatory support capability. An OEM partner that only ships products but cannot support your in-country registration process is half a supplier. A complete OEM partner provides: Device Master Record excerpts, sterilization validation reports (if applicable), biocompatibility test reports per ISO 10993, and stability study protocols with raw data — not just summary certificates.
4. Confirm private-label readiness. If you are building your own brand in your market, confirm that the manufacturer offers full OEM/ODM services including custom cassette housing color, custom pouch printing, and branded box packaging — with a typical sample turnaround of 7-14 days from artwork approval.
5. Validate no channel conflict. Some Chinese IVD manufacturers compete with their own distributors by selling under their own brand in export markets. Verify that your OEM partner does not market its own brand in your target territory — this is a fundamental trust requirement for long-term distribution relationships.

The lead time from confirmed OEM order to FOB shipment is typically 4-6 weeks for standard panel configurations. For custom-branded packaging with localized IFU, add 2-3 weeks for artwork approval and printing. MOQ per SKU ranges from 10,000 to 50,000 units depending on the manufacturer and the complexity of the branding requirements.

Frequently Asked Questions

Can I get a single cassette that tests for Dengue, Typhoid, and Malaria simultaneously?

No. Malaria rapid tests require erythrocyte lysis (breaking red blood cells) to release intraerythrocytic parasite antigens. This lysis buffer is chemically incompatible with the native plasma/serum-based detection systems used for Dengue NS1 antigen and Typhoid IgG/IgM antibodies. Attempting to combine them on one cassette would produce unreliable results due to hemoglobin interference, cellular debris, and disrupted capillary flow dynamics. The correct approach is to source Dengue+Typhoid as a paired panel (same storage, same sample, same supplier) and Malaria as a separate line item with its own dedicated lysis buffer.

What is the correct storage temperature for Dengue NS1 and Typhoid IgG/IgM rapid tests?

4-30°C, not 2-30°C. At 2°C, buffer precipitation can occur in some formulations, and the risk of accidental freeze-thaw cycling during transit is significantly higher when the lower bound is set at 2°C rather than 4°C. Verify that the manufacturer’s real-time stability data supports 24-month shelf life at 4-30°C, and check that the IFU (Instructions for Use) document states 4-30°C consistently — discrepancies between the IFU, the box label, and the stability report are a red flag for quality system gaps.

What certifications should I require for government tender qualification?

At minimum: ISO 13485 + CE IVDR (not IVDD) + MDSAP. MDSAP is particularly valuable because a single audit satisfies quality system requirements for FDA (USA), Health Canada, TGA (Australia), ANVISA (Brazil), and PMDA (Japan). Additionally, request a Certificate of Free Sale from China’s NMPA, batch-specific Certificates of Analysis, and the manufacturer’s ISO 14971 risk management file summary. For markets with specific national requirements (e.g., India’s CDSCO, Indonesia’s Ministry of Health), confirm that the manufacturer can provide the supplementary documentation required for in-country registration.

What is the typical lead time for OEM-branded tropical disease rapid test kits?

4-6 weeks from confirmed order to FOB shipment for standard configurations. Custom-branded packaging with localized IFU adds approximately 2-3 weeks for artwork approval and printing setup. Sample turnaround for artwork proofing and evaluation is typically 7-14 days. The MOQ per SKU ranges from 10,000 to 50,000 units depending on branding complexity and the manufacturer’s production scheduling.

Should I source Dengue and Typhoid tests from the same manufacturer or different suppliers?

From the same manufacturer, for three concrete reasons. First, consolidated logistics: both products share the same storage conditions (4-30°C) and can be shipped, stored, and distributed together — reducing cold-chain management complexity. Second, unified regulatory documentation: a single Device Master Record package from one ISO 13485/MDSAP facility simplifies your in-country registration process across all SKUs. Third, volume pricing: consolidated order volume across multiple SKUs from one supplier yields better per-unit pricing than splitting your purchase across multiple vendors.

About the Author

Angela Qin

International Sales Director at Hangzhou Testsea Biotechnology Co., Ltd. (Testsealabs)

Angela Qin is the International Sales Director at Hangzhou Testsea Biotechnology Co., Ltd. (Testsealabs), with 10+ years of experience in the in vitro diagnostic (IVD) and veterinary product industry. Founded in 2015 with the pursuit “serving society, health world,” Testsealabs specializes in the R&D, production, and sales of rapid diagnostic products, including tests for infectious diseases, cardiovascular diseases, inflammation, tumor markers, drug abuse, and pregnancy. Leveraging proprietary platforms (immunological detection, molecular biology, protein chip, and biological raw materials), Angela helps global distributors, hospitals, public health institutions, and veterinary clients source reliable, high-quality diagnostic solutions from China. Testsealabs’ products are widely used in rapid diagnosis, treatment monitoring, maternal and child healthcare, drug and alcohol testing, and have been sold to over 100 countries worldwide.

Facebook: https://www.facebook.com/profile.php?id=61589658929835

LinkedIn: https://www.linkedin.com/jobs/